{"filings":[{"id":668956,"accession_number":"0001104659-26-066317","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2026-05-26T20:42:33+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Editas Medicine prices $125M public offering of shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 55,555,556 shares and warrants at $2.25 per unit; gross proceeds $125M before warrant exercise.","Warrants exercisable at $3.50/share, expire upon EDIT-401 Phase 1 data milestone or within 3 years.","If all warrants exercised, additional proceeds ~$194.4M; net proceeds estimated ~$117M.","Cash runway extended into second half of 2028 based on current plans.","Underwriters: Cantor Fitzgerald and Wells Fargo; closing expected May 27, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":649836,"accession_number":"0001104659-26-066021","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2026-05-26T12:07:16+00:00","items":["8.01"],"status":"ready","headline":"Editas Medicine suspends ATM offering program; $43.9M raised to date","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Notified TD Cowen of suspension and termination of March 21, 2025 prospectus supplement.","No further ATM sales until new prospectus or registration statement is filed and effective.","Sales Agreement with TD Cowen remains in full force and effect.","Aggregate sales to date: 14,327,365 shares for $43.9M gross proceeds before expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":648597,"accession_number":"0001104659-26-065908","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2026-05-26T10:09:56+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"EDIT-401 preclinical data shows ~90% mean reductions in LDL-C, Lp(a), ApoB in NHPs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single dose achieved ≥90% mean reduction in LDL-C, rapid and dose-dependent, durable through 6 months in NHPs.","Achieved ~90% mean reduction in Lp(a) and ApoB, supporting unified LDLR upregulation mechanism.","Well-tolerated at therapeutically relevant dose 1.5 mg/kg; no adverse observations in ongoing GLP toxicology.","Plans to submit CTN in Australia by mid-2026; first-in-human HeFH trial later in 2026; early human PoC data by end of 2026.","Received positive pre-IND feedback from FDA on nonclinical package, CMC plans, and study design."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77082,"accession_number":"0001650664-26-000049","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2026-05-14T10:16:31+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Editas reports EDIT-401 achieves ≥90% LDL-C reduction in NHPs; durable through 6 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single dose of EDIT-401 achieved ≥90% mean LDL-C reduction across all dose groups in non-human primates.","Reduction durable through ~6 months; achieved with 10-40% functional editing of LDLR alleles and ≥6-fold hepatic LDLR protein increase.","Promising preclinical safety profile: no adverse clinical observations at 1.5 mg/kg; undetectable oocyte delivery.","Data in Ldlr loss-of-function mice suggest dose adjustments may not be needed for HeFH patients.","Data support broader upregulation platform and continued advancement toward first-in-human clinical development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94406,"accession_number":"0001650664-26-000043","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Editas Q1 net loss $25M ($0.26/share); EDIT-401 on track for human data by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $25.0M ($0.26 per share) vs. $76.1M ($0.92) in Q1 2025; no restructuring charges this quarter.","Cash and equivalents $123.6M as of March 31; expected to fund operations into Q3 2027.","R&D expenses down 34% YoY to $17.6M due to reni-cel discontinuation and headcount reduction.","EDIT-401 preclinical shows >90% mean LDL-C reduction; first-in-human trial for HeFH expected in H2 2026 with proof-of-concept data by year-end.","USPTO reaffirmed Broad Institute's priority in CRISPR/Cas9 patent interference, supporting Editas' licensed IP."],"consensus_eps_estimate":-0.269,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":2831000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94405,"accession_number":"0001650664-26-000030","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Editas Medicine dismisses EY, appoints PwC as independent auditor for FY2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed EY effective April 1, 2026; EY notified on April 2, 2026.","PwC appointed as new independent registered public accounting firm for FY ending Dec 31, 2026.","No disagreements or reportable events with EY during FY2024, FY2025, or interim period.","EY's letter to SEC filed as Exhibit 16.1, agreeing with the disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106780,"accession_number":"0001650664-26-000027","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"USPTO reaffirms Broad Institute's CRISPR/Cas9 patent priority; Editas' licensed patents upheld","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["PTAB issued third favorable decision for Broad over CVC on CRISPR/Cas9 editing in eukaryotic cells.","CVC retains the right to appeal to the U.S. Court of Appeals for the Federal Circuit.","Editas' exclusive license to the CRISPR/Cas9 patents at issue remains intact; other in-licensed patents not impacted.","CEO Gilmore O'Neill cites confidence in IP, highlighting EDIT-401 with >90% mean LDL reduction in NHPs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106779,"accession_number":"0001650664-26-000013","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Editas Medicine Q4 2025 net loss $5.6M; EDIT-401 IND on track mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $146.6M at Dec 31, 2025, down from $269.9M; runway into Q3 2027.","Net loss Q4 2025 $5.6M ($0.06/sh) vs $45.4M ($0.55/sh) in Q4 2024.","Full year 2025 net loss $160.1M ($1.80/sh) vs $237.1M ($2.88/sh) in 2024.","Lead candidate EDIT-401 achieved >90% mean LDL-C reduction in preclinical; IND/CTA submission expected by mid-2026.","First-in-human trial in HeFH planned for 2026; early proof-of-concept data targeted by year-end 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123086,"accession_number":"0001650664-25-000153","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Editas Q3 net loss narrows to $25.1M; preclinical EDIT-401 shows >90% LDL-C reduction; cash runway extended to Q3 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $25.1M ($0.28/sh) vs $62.1M ($0.75/sh) in Q3 2024; collaboration revenue rose to $7.5M from $0.1M on BMS milestone.","R&D expenses fell 58% to $19.8M; G&A expenses fell 32% to $12.3M, both reflecting reni-cel program discontinuation.","Cash & securities $165.6M at Sept. 30; $17.8M raised via ATM in Q3; runway extended into Q3 2027, enabling EDIT-401 progression.","Preclinical data: single dose of EDIT-401 achieved ≥90% LDL-C reduction in NHPs within 48 hours; durability shown in 3-month mouse study.","On track to file IND/CTA for EDIT-401 by mid-2026; initial human proof-of-concept data expected by year-end 2026."],"consensus_eps_estimate":-0.3022,"consensus_eps_actual":-1.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":15779000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123085,"accession_number":"0001650664-25-000148","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Editas reports in vivo proof-of-concept for EDIT-401 with ≥90% LDL-C reduction in NHPs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EDIT-401 achieved ≥90% mean LDL-C reduction in non-human primates within 48 hours of a single dose.","Same ≥90% LDL-C reduction observed in mice with high baseline LDL-C and reduced LDLR function.","LDL-C reductions maintained in mouse models over a three-month study.","≥6-fold mean increase in LDLR protein in NHP liver, requiring only moderate functional editing of LDLR alleles.","Data presented at ESGCT 32nd Annual Congress; no financial guidance or regulatory milestones changed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139777,"accession_number":"0001650664-25-000134","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Editas Medicine nominates EDIT-401 as lead in vivo candidate; ~90% LDL-C reduction in NHPs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EDIT-401 achieved ~90% mean LDL-C reduction after single dose in non-human primates across all doses (1.5-4 mg/kg), sustained for one month.","Observed at least 6-fold mean increase in LDLR protein levels; no adverse effects; transient liver enzyme increases resolved within one week.","Plans to submit IND/CTA for EDIT-401 by mid-2026 with human proof-of-concept data targeted by end of 2026.","Company re-confirmed cash runway into Q2 2027 based on existing cash and Vertex payments.","Editas will focus resources on EDIT-401 advancement; intends to identify additional target cell type by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139776,"accession_number":"0001650664-25-000123","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Editas Q2 net loss $53.2M; selects in vivo lead candidate in Sept; BMS CAR T milestone triggered","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $53.2M ($0.63/share) vs $67.6M loss a year ago; revenue $3.6M from BMS milestone.","Cash $178.5M at June 30 (down from $269.9M at Dec 2024); runway into Q2 2027.","R&D expense fell $38M to $16.2M on reni-cel discontinuation; restructuring charges $26.1M.","First IND/CTA accepted for CD19 HD Allo CAR T with BMS, triggering milestone payment to Editas.","On track to name lead in vivo candidate Sept 2025, file IND mid-2026, achieve POC by end 2026."],"consensus_eps_estimate":-0.3846,"consensus_eps_actual":-1.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":8236000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157346,"accession_number":"0001650664-25-000106","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Editas reports 58% HBG1/2 editing in NHPs after single tLNP dose at 5 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean on-target editing of 58% in HSCs at 5 months post single IV dose of proprietary tLNP, exceeding ≥25% therapeutic threshold.","Data presented at EHA 2025; supports in vivo approach for sickle cell disease and beta thalassemia.","Biodistribution shows significant liver de-targeting vs. standard LNPs in NHPs.","Uses AsCas12a to edit HBG1/2 promoters, mimicking hereditary persistence of fetal hemoglobin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157345,"accession_number":"0001650664-25-000086","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Editas Medicine stockholders approve increase in authorized shares and amend 2015 Stock Incentive Plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to increase authorized common stock from 195M to 390M shares; total capital stock from 200M to 395M.","Stockholders approved amendment and restatement of 2015 Stock Incentive Plan, extending term to 10 years and eliminating evergreen provision.","Re-elected Jessica Hopfield, Ph.D., and David Scadden, M.D. as Class III directors until the 2028 annual meeting.","Advisory vote on executive compensation passed with ~60% for; one-year frequency for future say-on-pay votes approved.","Ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157344,"accession_number":"0001650664-25-000081","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Editas reports in vivo HSC editing up to 48% HBG1/2, exceeding 25% therapeutic threshold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single dose of proprietary tLNP achieved up to 47% HBG1/2 editing in NHP HSCs and 48% in humanized mouse long-term HSCs.","Both studies exceeded the ≥25% editing threshold predicted for therapeutic benefit in sickle cell disease and beta thalassemia.","Preliminary biodistribution shows significant liver de-targeting with tLNP vs. standard LNPs.","Data presented at ASGCT 2025; supports development of in vivo gene editing medicine using AsCas12a-based reni-cel approach.","Clinical validation of HBG1/2 promoter editing previously demonstrated with reni-cel leading to increased HbF and total Hb."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157343,"accession_number":"0001650664-25-000077","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Editas reports in vivo POC data for undisclosed liver target; ~70% editing in mice","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Maximal liver editing of ~70% in disease-specific mouse model using LNP-delivered CRISPR/Cas cargo.","Robust target protein upregulation with >80% reduction of disease-associated biomarker in mice.","In cynomolgus monkey hepatocytes: >50% target gene editing and >15-fold protein upregulation.","Company expects to disclose the disease target and development candidate later in 2025.","Data presented at ASGCT Annual Meeting; additional oral presentation at TIDES USA on May 21."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157342,"accession_number":"0001650664-25-000071","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Editas Q1 net loss $76.1M ($0.92/share); cash $221M runway into Q2 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $76.1M ($0.92 per share) vs $62.0M loss in Q1 2024; revenue $4.7M (up from $1.1M).","R&D expenses fell to $26.6M from $48.8M; restructuring charges $40.9M from reni-cel discontinuation.","Cash, equivalents, and marketable securities $221.0M; expected to fund operations into Q2 2027.","Amy Parison appointed CFO; previously SVP Finance and Corporate Controller at Editas since 2022.","Federal Circuit vacated PTAB decision on CRISPR/Cas9 patents; remanded for further review."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":4658000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175720,"accession_number":"0001650664-25-000031","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Editas Medicine CFO resigns; Amy Parison appointed as CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erick Lucera resigns as EVP, CFO effective March 28, 2025.","Amy Parison, previously SVP Finance, appointed SVP, CFO and Treasurer effective March 28, 2025.","Parison receives $415k base salary, 40% target bonus, and option for 34,672 shares vesting monthly over 4 years.","Parison joined Editas in Aug 2022 as VP Finance, Corporate Controller, promoted to SVP Finance Jan 2025.","No arrangement or understanding behind Parison's selection; no reportable transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175719,"accession_number":"0001650664-25-000020","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Editas posts Q4 net loss $45.4M ($0.55/sh); ends reni-cel, cuts 65% staff","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss $45.4M vs $18.9M in Q4 2023; full-year net loss $237.1M vs $153.2M.","Cash $269.9M; operational runway into Q2 2027 includes $45-55M in restructuring costs.","Ended reni-cel development due to failed partnership search; workforce reduced ~65%.","On track to declare in vivo HSC and liver development candidates via gene upregulation mid-2025.","No future quarterly earnings conference calls."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175718,"accession_number":"0001650664-25-000003","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Editas Medicine reports $270M cash, new in vivo preclinical data, and 2025-2027 strategic priorities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents, marketable securities ~$270M as of Dec 31, 2024; operational runway into Q2 2027.","Achieved in vivo editing of hematopoietic stem cells in non-human primates using proprietary tLNPs; further optimization underway.","Achieved proof of concept for AsCas12a LNP delivery in liver cells in non-human primates; also demonstrated upregulation in mice.","Anticipates declaring two in vivo development candidates by mid-2025: HSC for sickle cell/beta thalassemia and liver for undisclosed indication.","Strategic priorities through 2027: submit at least one IND/CTA by mid-2026, start human trials H2 2026, initiate late-stage trial H2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192659,"accession_number":"0001650664-24-000144","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":[],"status":"ready","headline":"Editas Medicine CMO Baisong Mei steps down; separation terms outlined","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Baisong Mei to step down as CMO effective Dec 31, 2024; transition period ends Jan 31, 2025.","Separation agreement provides 12 months base salary, COBRA contributions, and potential 2024 bonus.","Vested stock option exercise extended to Dec 31, 2025; unvested RSUs vest through 90 days post-separation.","Agreement includes standard release, non-disparagement, and confidentiality clauses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192658,"accession_number":"0001650664-24-000141","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["2.05","7.01","8.01","9.01"],"status":"ready","headline":"Editas halts reni-cel, cuts 65% workforce, shifts to in vivo gene editing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinues ex vivo reni-cel program for sickle cell and beta thalassemia; ends partnering process.","Reduces workforce by ~180 positions (65%); costs of $55-70M for discontinuation, $14-18M for reduction.","Cash runway extended to Q2 2027; focuses on in vivo pipeline, with human proof-of-concept target in ~2 years.","CMO Baisong Mei steps down Dec 31; board members Emma Reeve and Meeta Chatterjee resign; Jessica Hopfield becomes Chair."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192657,"accession_number":"0001650664-24-000138","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Editas reports positive RUBY trial data: 27/28 SCD patients VOE-free, HbF 48% at month 6","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of Oct 29, 2024, 28 SCD patients treated; 27 VOE-free post-reni-cel; median follow-up 9.5 months.","Mean total hemoglobin increased from 9.8 g/dL at baseline to 13.8 g/dL at Month 6 (n=18).","Mean HbF percentage reached 48.1% at Month 6; F-cells >90% from Month 4; MCH-F above anti-sickling threshold.","All evaluable patients engrafted; median time to neutrophil engraftment 23 days, platelet 25 days.","Two SAEs possibly related to reni-cel reported; safety consistent with myeloablative conditioning."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192656,"accession_number":"0001650664-24-000120","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Editas Q3 net loss widens to $62.1M; cash runway extended into Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 net loss of $62.1M ($0.75/sh) vs $45.0M ($0.55/sh) in Q3 2023; R&D spend up $7.1M.","Cash, equivalents and securities $265.1M at Sept 30; with DRI $57M upfront totals ~$322.1M.","In vivo preclinical proof of concept for HBG1/2 editing in HSPCs using targeted LNP achieved.","Reni-cel partnering process with Moelis & Co underway; 28-patient RUBY update at ASH in December.","Collaboration revenue fell to $0.1M from $5.3M on prior-year Vor Bio upfront payment."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":1710000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192655,"accession_number":"0001650664-24-000114","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Editas achieves in vivo preclinical proof of concept for sickle cell; seeks partner for reni-cel","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Achieved 29% HSPC editing and 20% HbF-expressing red blood cells in humanized mice after single dose using proprietary tLNP.","Initiated process to partner or out-license reni-cel; engaged Moelis & Company to lead global process.","Q3 2024 cash, equivalents, and marketable securities ~$265M; ~$320M after $57M upfront from DRI Healthcare.","On track to present substantive RUBY trial SCD data at ASH December 2024; EdiTHAL data by year-end 2024.","Company will not host Q3 2024 earnings call; strategic update webinar held October 22, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192654,"accession_number":"0001650664-24-000111","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Editas Medicine monetizes Vertex license fees for $57M upfront from DRI Healthcare Trust","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront cash payment of $57M from DRI subsidiary for up to 100% of future annual license fees ($5M-$40M/year) and a mid-double-digit % of $50M contingent payment under Vertex Cas9 license.","Non-dilutive capital to fund pipeline development and strategic priorities; Editas retains 2024 fixed fees and a mid-single-digit million milestone payment from Vertex.","Purchase agreement has no financial covenants; potential liquidated damages or termination fees of one-to-two times the upfront payment under specified conditions.","Vertex license (Dec 2023) covers Cas9 technology for ex vivo BCL11A gene editing in sickle cell disease and beta thalassemia, including CASGEVY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209108,"accession_number":"0001650664-24-000094","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Editas Medicine Q2 2024 net loss $67.6M ($0.82/share), cash $318.3M, on track for clinical data by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $67.6M ($0.82 per share) vs $40.3M ($0.56 per share) in Q2 2023.","Cash and equivalents $318.3M as of June 30, 2024 (down from $376.8M Q1); runway into 2026.","R&D expenses $54.2M, up $24.4M driven by reni-cel program and in vivo research.","On track to present additional clinical data from RUBY (SCD) and EdiTHAL (TDT) trials by year-end 2024.","Completed enrollment of adult cohorts for both RUBY and EdiTHAL; adolescent cohort enrolled for RUBY."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":1649000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226969,"accession_number":"0001650664-24-000081","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Editas Medicine director Akshay Vaishnaw resigns from Board effective June 30, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Akshay Vaishnaw submitted resignation on June 27, 2024; effective June 30, 2024.","Resignation not due to any disagreement with Company’s operations, policies, or practices.","No replacement or additional board changes announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226968,"accession_number":"0001650664-24-000078","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Editas reni-cel RUBY trial: 18 SCD patients VOE-free; EdiTHAL: 7 TDT patients transfusion-free","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["18 SCD patients free of vaso-occlusive events post-reni-cel (follow-up 2.4-22.8 months); mean total Hb >14 g/dL, HbF >40%.","7 TDT patients transfusion-free for 4.1-12.8 months; mean total Hb 12.1 g/dL at month 6, HbF 10.9 g/dL.","No serious adverse events related to reni-cel in either trial; safety profile consistent with myeloablative conditioning.","Median neutrophil engraftment 23 days (SCD and TDT); platelet engraftment 24 days (SCD), 38 days (TDT).","Further clinical update from both trials expected by year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226967,"accession_number":"0001650664-24-000050","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Editas Medicine stockholders elect Class II directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Meeta Chatterjee, Andrew Hirsch, Gilmore O'Neill as Class II directors for term until 2027 annual meeting.","Advisory say-on-pay approved with 38,609,828 votes for, 2,769,887 against, 205,788 abstentions.","Ratified Ernst & Young as independent auditor for fiscal 2024 with 57,952,408 votes for, 362,117 against, 1,036,297 abstentions.","Broker non-votes of 17,765,319 on director election and say-on-pay; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226966,"accession_number":"0001650664-24-000034","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Editas Medicine Q1 net loss $62M; cash $376.8M; reni-cel adult cohort enrollment complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 net loss $62.0M ($0.76/share) vs $49.0M ($0.71) in Q1 2023; collaboration revenue fell to $1.1M from $9.9M.","Cash, equivalents, and marketable securities $376.8M at March 31, 2024; runway into 2026.","R&D expenses rose to $48.8M from $37.8M driven by reni-cel clinical and manufacturing costs.","Completed adult cohort enrollment in RUBY trial for sickle cell disease; enrolled multiple adolescent patients.","Extended Bristol Myers Squibb collaboration by two years; CAFC oral arguments held for CRISPR patent interference."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":1135000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245907,"accession_number":"0001650664-24-000006","cik":1650664,"company_name":"Editas Medicine, Inc.","ticker":"EDIT","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Editas reports Q4 net loss of $18.9M; Vertex license deal provides cash runway into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $18.9M ($0.23 per share) vs $60.7M ($0.88) in Q4 2022; revenue boosted by Vertex license.","Cash $427.1M as of Dec 31, 2023; with Vertex license payments, runway expected into 2026.","FDA aligns that RUBY trial is single Phase 1/2/3 to support BLA; adolescent cohort enrollment initiated.","Entered license agreement with Vertex for Cas9 for ex vivo SCD/beta thal; $50M contingent upfront plus annual fees."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":78123000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":334349941.79971987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}